1. Home
  2. LOAN vs ATNM Comparison

LOAN vs ATNM Comparison

Compare LOAN & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

SELL

Current Price

$3.29

Market Cap

38.8M

Sector

Real Estate

ML Signal

SELL

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$1.49

Market Cap

31.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LOAN
ATNM
Founded
1989
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.8M
31.4M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
LOAN
ATNM
Price
$3.29
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $4.00
AVG Volume (30 Days)
24.3K
★ 268.1K
Earning Date
10-21-2026
11-27-2026
Dividend Yield
★ 13.71%
N/A
EPS Growth
N/A
★ 14.17
EPS
0.32
★ 0.71
Revenue
★ $8,666,307.00
$90,000.00
Revenue This Year
N/A
$38,788.89
Revenue Next Year
N/A
N/A
P/E Ratio
$10.05
★ $2.31
Revenue Growth
N/A
★ 11.11
52 Week Low
$3.19
$0.74
52 Week High
$5.01
$1.72

Technical Indicators

Market Signals
Indicator
LOAN
ATNM
Relative Strength Index (RSI) 39.68 54.93
Support Level N/A $0.97
Resistance Level $4.50 $1.53
Average True Range (ATR) 0.09 0.12
MACD 0.00 0.00
Stochastic Oscillator 38.72 51.90

Price Performance

Historical Comparison
LOAN
ATNM

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: